Netherlands Pharmaceuticals & Healthcare Report

Published 30 April 2015

  • 114 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Netherlands Pharmaceuticals & Healthcare Report

BMI View: The healthcare market in the Netherlands will continue to offer considerable commercial opportunities. As a part of the Health Insurance Act, implemented in 2006, private insurance for curative care and supplemental benefits is mandatory for the entire population. However, the Act is based on the principles of managed competition: insurers and providers of care compete on price and quality while the government has set certain rules to guarantee universal access to good-quality care - creating a highly competitive business environment and acting as a challenge to company revenue streams.

Headline Expenditure Projections

  • Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.85bn (USD6.43bn) in 2015; -1.2% in local currency terms and -18.9% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: EUR73.31bn (USD98.23bn) in 2014 to EUR74.73bn (USD82.20bn) in 2015; +1.9% in local currency terms and -16.3% in US dollar terms. Forecast revised upwards from last quarter due to the release of WHO confirmed data.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our ratings for Q315. The country has moved up a position from last quarter. At 64.7, its overall RRI score remains only slightly below the regional average of 66.8. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

April 2015

The Netherlands' Medicines Evaluation Board (MEB) has suspended the marketing authorisations for the generic medicinal products irbesartan torrent and irbesartan hydrochlorothiazide torrent. These products are currently not available in the market. According to the MEB, the trial that served as the basis of admission for the products was not...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018)
16
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
24
Netherlands
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
26
OTC Medicine Market Forecast
26
Table: OTC Medicine Sales Indicators By Category, 2008-2010
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018)
31
Other Healthcare Data
32
Table: Number Of Physicians By Type, 2007-2010
33
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Netherlands - Economic Activity
38
Industry Risk Reward Ratings
39
Western Europe Risk/Reward Ratings
39
Netherlands Risk/Reward Ratings
44
Rewards
44
Risks
44
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Healthcare Sector
48
Healthcare Funding
50
Health Insurance
51
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
52
Healthcare Insurance Developments
56
Table: Biosimilars Approved In The EU
57
Research And Development
57
Clinical Trials
60
Biotechnology
63
Regulatory Development
64
Regulatory Developments
65
Intellectual Property Regime
67
Pricing Regime
68
Reimbursement Regime
70
Competitive Landscape
73
Pharmaceutical Industry
73
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
73
Recent Company Activity
75
Pharmaceutical Wholesale Sector
77
Pharmaceutical Retail Sector
78
Company Profile
81
DSM
81
Qiagen
85
Pharming Group
88
Merck & Co
92
Pfizer
95
GlaxoSmithKline
98
Sanofi
100
Novartis
102
Demographic Forecast
105
Demographic Outlook
105
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)
106
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)
107
Table: The Netherlands' Key Population Ratios, 1990-2020
108
Table: The Netherlands' Rural And Urban Population, 1990-2020
108
Glossary
109
Methodology
111
Pharmaceutical Expenditure Forecast Model
111
Healthcare Expenditure Forecast Model
111
Notes On Methodology
112
Risk/Reward Ratings Methodology
113
Ratings Overview
114
Table: Pharmaceutical Risk/Reward Ratings Indicators
114
Indicator Weightings
115

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc